BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Roberts KE, Rickett K, Feng S, Vagenas D, Woodward NE. Exercise therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer. Cochrane Database Syst Rev 2020;1:CD012988. [PMID: 31994181 DOI: 10.1002/14651858.CD012988.pub2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Davies S, Voutsadakis IA. Adherence to adjuvant hormonal therapy in localised breast cancer. Eur J Cancer Care (Engl) 2022;:e13729. [PMID: 36207823 DOI: 10.1111/ecc.13729] [Reference Citation Analysis]
2 Ahlstedt Karlsson S, Henoch I, Olofsson Bagge R, Wallengren C. Person-centred support programme (RESPECT intervention) for women with breast cancer treated with endocrine therapy: a feasibility study. BMJ Open 2022;12:e060946. [PMID: 36198470 DOI: 10.1136/bmjopen-2022-060946] [Reference Citation Analysis]
3 Desideri I, Lucidi S, Francolini G, Meattini I, Ciccone LP, Salvestrini V, Valzano M, Morelli I, Angelini L, Scotti V, Bonomo P, Greto D, Terziani F, Becherini C, Visani L, Livi L. Use of an alfa-lipoic, Methylsulfonylmethane, Boswellia serrata and Bromelain dietary supplement (OPERA®) for aromatase inhibitors-related arthralgia management (AIA): a prospective phase II trial (NCT04161833). Med Oncol 2022;39:113. [PMID: 35666314 DOI: 10.1007/s12032-022-01723-x] [Reference Citation Analysis]
4 Roberts KE, Adsett IT, Rickett K, Conroy SM, Chatfield MD, Woodward NE. Systemic therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer. Cochrane Database Syst Rev 2022;1:CD013167. [PMID: 35005781 DOI: 10.1002/14651858.CD013167.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
5 Sen EI. What are the effects of systemic therapies for the prevention and treatment of aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer? - A Cochrane Review summary with commentary. J Musculoskelet Neuronal Interact 2022;22:301-4. [PMID: 36046985] [Reference Citation Analysis]
6 Saito T, Ono R. Physical Activity in Patients with Breast Cancer. Physical Therapy and Research in Patients with Cancer 2022. [DOI: 10.1007/978-981-19-6710-8_13] [Reference Citation Analysis]
7 de Sire A, Lippi L, Ammendolia A, Cisari C, Venetis K, Sajjadi E, Fusco N, Invernizzi M. Physical Exercise with or without Whole-Body Vibration in Breast Cancer Patients Suffering from Aromatase Inhibitor—Induced Musculoskeletal Symptoms: A Pilot Randomized Clinical Study. JPM 2021;11:1369. [DOI: 10.3390/jpm11121369] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
8 Zhu XY, Li Z, Chen C, Feng RL, Cheng BR, Liu RY, Wang RT, Xu L, Wang Y, Tao X, Zhao P. Physical Therapies for Psychosomatic Symptoms and Quality of Life Induced by Aromatase Inhibitors in Breast Cancer Patients: A Systematic Review and Meta-Analysis. Front Oncol 2021;11:745280. [PMID: 34868943 DOI: 10.3389/fonc.2021.745280] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
9 Oza S. Aromatase Inhibitor-induced Musculoskeletal Syndrome: a Review of Rehabilitation Interventions. Curr Phys Med Rehabil Rep 2021;9:119-26. [DOI: 10.1007/s40141-021-00318-3] [Reference Citation Analysis]
10 Cai Y, Li J, Gao Y, Yang K, He J, Li N, Tian J. A systematic review of recommendations on screening strategies for breast cancer due to hereditary predisposition: Who, When, and How? Cancer Med 2021;10:3437-48. [PMID: 33932123 DOI: 10.1002/cam4.3898] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Hannoun-Levi JM, Chamorey E, Boulahssass R, Polgar C, Strnad V; Breast Cancer Working Group of the GEC-ESTRO. Endocrine therapy with accelerated Partial breast irradiatiOn or exclusive ultra-accelerated Partial breast irradiation for women aged ≥ 60 years with Early-stage breast cancer (EPOPE): The rationale for a GEC-ESTRO randomized phase III-controlled trial. Clin Transl Radiat Oncol 2021;29:1-8. [PMID: 33997321 DOI: 10.1016/j.ctro.2021.04.005] [Reference Citation Analysis]
12 Braun C, Grummich K, Rüschemeyer G. Bewegungstherapien für Menschen mit Krebserkrankungen. Forum 2020;35:465-472. [DOI: 10.1007/s12312-020-00854-4] [Reference Citation Analysis]
13 Tenti S, Correale P, Cheleschi S, Fioravanti A, Pirtoli L. Aromatase Inhibitors-Induced Musculoskeletal Disorders: Current Knowledge on Clinical and Molecular Aspects. Int J Mol Sci 2020;21:E5625. [PMID: 32781535 DOI: 10.3390/ijms21165625] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
14 Roberts K, Rickett K, Feng S, Vagenas D, Woodward N. Letter to the editor: re Lu et al. Support Care Cancer 2021;29:1-2. [PMID: 32417967 DOI: 10.1007/s00520-020-05523-9] [Reference Citation Analysis]